How does metagenomic testing detect infections faster in intensive care?
mNGS finds far more pathogens than culture in ICU patients, especially on antibiotics, but it is not yet proven to improve survival.
Covers: How metagenomic sequencing works for infection diagnosis, turnaround times compared with culture and PCR, and evidence on sensitivity and specificity in critically ill and ICU patients. Does not cover detailed lab protocols, sequencing chemistry, or cost-effectiveness modeling.
Also answers: How does metagenomics testing detect infections faster in intensive care? · How fast is metagenomic testing for infections in ICU? · Does metagenomic sequencing diagnose sepsis faster than culture? · Metagenomic testing for infections in critically ill patients
- One page for this question6 other ways of asking lead here
- 5 independent sourcesEvery claim links to what supports it
- Joins the mapLinked as related pages appear
- Clean discussionScreened before anything appears
The short answer
Interpretation AI-prepared starting mapMetagenomic next-generation sequencing (mNGS) sequences all microbial DNA in a sample at once instead of waiting for organisms to grow, so it can name bacteria, DNA viruses and fungi directly. In ICU studies it detects far more pathogens than culture: in 87 critically ill sepsis patients (mostly bronchoalveolar lavage fluid), mNGS was positive in 92%…12
Read the full explanation and caveats
At a glance
The picture in numbers
Live · updated just now
- mNGS92%
- culture36%
- culture, no antibiotics30.4%
- culture, on antibiotics10.4%
- mNGS, no antibiotics52.6%
- mNGS, on antibiotics50.8%
75.3%
75 in every 100
58.6%
59 in every 100
The evidence behind it
6 sources- Reviews of many studies1
- Other studies and data4
- Background1
When it was published
Newest from 2026
| Source | Kind | Year |
|---|---|---|
| Influence of Ongoing Antibiotic Therapy on the Detection of Pathogenic Microorganisms Using Metagenomic Next-Generation Sequencing and Blood Culture in ICU Patients. | Other studies and data | 2026 |
| The value of metagenomic next-generation sequencing in lower respiratory tract infections among critically ill patients in the ICU | Other studies and data | 2026 |
| Clinical Characteristics and the Effect of Timing for Metagenomic Next-Generation Sequencing in Critically Ill Patients with Sepsis | Other studies and data | 2022 |
| Metagenomic Sequencing in the ICU for Precision Diagnosis of Critical Infectious Illnesses | Other studies and data | 2023 |
| Oxford Nanopore Sequencing, a Promising Technology for Precision Diagnostics in Intensive Care Units: A Narrative Review. | Reviews of many studies | 2026 |
| Ten-year-old Willow among children to benefit from pioneering same-day test to spot infections | Background | 2026 |
The community around it
No one has added to this page yet. Firsthand experience, a newer study or a different reading of the numbers would show up here, credited to you.
Test what you remember
Fill in the blank: ?% of samples where mNGS agreed with blood culture
Drag the slider to fill in the blank
Did this answer your question?
Be the first to voteIn brief
mNGS reads all microbial DNA in a sample at once, so it can identify bacteria, DNA viruses and fungi without waiting for growth or guessing targets.3
Evidence-backedIn ICU studies it detects substantially more pathogens than culture — 92% vs 36% in one sepsis cohort, with extra viruses and fungi found.1
Evidence-backedIts main practical advantage may be in patients already on antibiotics: culture yield collapsed from 30.4% to 10.4%, while mNGS bacterial detection held near 50%.2
Evidence-backedReliability is only partly characterised: concordance with blood culture was 75.3% and negative predictive value 88.0%, without a true gold standard.2
Interpretation
Your turn
Have your say
See where others stand. Join free to add your perspective. One answer per account.
How do you feel about this?
No votes yetQuick questions from connected pages
What it means for you
Which fits you?
Pick the situation closest to yours. Each answer says what it rests on.
If a critically ill patient is already on antibiotics and cultures come back negative
mNGS may still detect bacteria, since culture yield fell to 10.4% on antibiotics while mNGS bacterial detection stayed near 50%; treat it as a complement to cultures, not a replacement.2
Evidence-backedIf the suspected infection is in the lower respiratory tract
bronchoalveolar lavage is the most studied sample type, and mNGS has shown an advantage over conventional testing for bacteria and DNA viruses, though not for RNA viruses.14
Evidence-backedIf an mNGS result comes back negative
a negative result is reassuring but not conclusive: negative predictive value against blood culture was 88.0%, so clinical judgement still matters.2
Evidence-backedIf you are deciding whether to fund or adopt mNGS in an ICU
treat the current evidence as promising but unproven for outcomes; reviewers call for larger studies with clinical endpoints, standardised pipelines and validation pathways.3
Evidence-backedIf speed matters most and near-patient testing is feasible
nanopore sequencing offers real-time, amplification-free analysis and portability suited to ICU settings, though its clinical validation is still developing.3
Evidence-backedThe full explanation
Interpretation AI-prepared starting mapMetagenomic next-generation sequencing (mNGS) sequences all microbial DNA in a sample at once instead of waiting for organisms to grow, so it can name bacteria, DNA viruses and fungi directly. In ICU studies it detects far more pathogens than culture: in 87 critically ill sepsis patients (mostly bronchoalveolar lavage fluid), mNGS was positive in 92% versus 36% for conventional culture (p<0.001), and it picked up more viruses and fungi. In 393 paired samples from 302 ICU patients, blood culture positivity fell from 30.4% to 10.4% when patients were on antibiotics, while mNGS bacterial detection stayed near 50% (52.6% vs 50.8%). Higher yield is not the same as proven better outcomes, and concordance with culture was 75.3%.12
- Evidence 17
- Interpretation 5
The full story · 4 chapters
01
How mNGS differs from culture and PCR
AI summary:mNGS reads all nucleic acid in a sample at once, unlike culture or PCR, and offers speed and breadth that suit intensive care.
Evidence-backed: Culture depends on living organisms growing in the lab, which takes days and fails when antibiotics have already suppressed the organisms. PCR looks for specific known targets, so it only finds what the test was designed to look for. mNGS instead reads all the nucleic acid in a sample and matches it against reference databases, so it can identify bacteria, viruses and fungi without a prior guess about what is present. Nanopore-based sequencing adds real-time, long-read, single-molecule analysis of native nucleic acid, allowing direct sequencing without amplification and rapid pathogen identification plus antimicrobial resistance profiling.32
Evidence-backed: The practical appeal in intensive care is speed and breadth: portability, rapid turnaround and potential point-of-care use make sequencing attractive where patients deteriorate within hours.3
02
What the ICU studies found about detection
AI summary:In ICU studies mNGS detected far more pathogens than culture, and its yield held up in patients already on antibiotics.
Evidence-backed: In 87 critically ill patients with sepsis, mostly sampled by bronchoalveolar lavage (84%), mNGS identified pathogens in 92% of samples versus 36% by conventional culture (p<0.001). Beyond the organisms culture found, mNGS detected additional viruses and fungi. Clinicians changed the antibiotic regimen for 72% of patients based on the mNGS report.1
Evidence-backed: In a larger cohort of 302 ICU patients (393 paired mNGS–blood culture samples), blood culture positivity was 30.4% without antibiotics but only 10.4% in patients already receiving them, while mNGS bacterial positivity was essentially unchanged (52.6% vs 50.8%). Blood culture yield fell sharply with longer antibiotic exposure; mNGS detection varied little.2
Evidence-backed: In lower respiratory tract infections among critically ill ICU patients, mNGS outperformed conventional microbiological testing for bacteria and DNA viruses, while conventional testing had a slight, non-significant edge for RNA viruses (p=0.305). Survivors showed a more diverse pathogen spectrum than non-survivors; Corynebacterium striatum dominated in survivors and Pseudomonas aeruginosa in the death group.4
03
Does it change treatment and outcomes?
AI summary:mNGS results often led to treatment changes and reported improvement, but without a control group they do not show better outcomes.
Evidence-backed: Treatment was adjusted on the basis of mNGS results in 128 patients in one ICU cohort: 59.4% were escalated, 25.8% had medications changed and 1.6% started new regimens. Clinicians reported symptom improvement in 58.6% of the patients whose treatment was adjusted. A random-forest model predicting outcomes from the data reached an AUC of 0.722.4
Evidence-backed: In the sepsis cohort, age (OR 1.036 per year, 95% CI 1.005–1.067) and the SOFA score on the day of mNGS sampling (OR 1.204, 95% CI 1.038–1.397) were independent risk factors for death at 28 days — a marker of how sick the patient was, not of the test itself.1
04
How reliable is it?
AI summary:Concordance with blood culture was 75.3% and negative predictive value 88.0%, but culture is an imperfect yardstick and validation is incomplete.
Interpretation: Against blood culture as comparator, mNGS concordance was 75.3% with a negative predictive value of 88.0% — meaning a negative mNGS result was usually, but not always, matched by a negative culture. Because culture itself misses organisms (especially under antibiotics), it is an imperfect yardstick, and these figures do not establish true sensitivity and specificity.2
Evidence-backed: The reviews are explicit that wider clinical use needs larger studies with clinical outcome endpoints, standardised bioinformatic pipelines and clearer validation pathways.3
Evidence-backed: Reporting has also reached the public: BBC News described metagenomics as a new way of detecting infections in intensive care patients, citing a child among those to benefit from a same-day test.5
Before you go
What to remember
Try to recall each hidden figure before you reveal it. Remembering, not rereading, is what makes it stick.
In ICU studies it detects substantially more pathogens than culture — vs 36% in one sepsis cohort, with extra viruses and fungi found.
Its main practical advantage may be in patients already on antibiotics: culture yield collapsed from to 10.4%, while mNGS bacterial detection held near 50%.
Reliability is only partly characterised: concordance with blood culture was and negative predictive value 88.0%, without a true gold standard.
Your reading
0 of 4 chaptersThis answer keeps changing
When new evidence or a better source comes in, this page is updated (it's on version 2, last changed 1 hour ago). Follow it to be told when that happens.
Ask this Sylo
Still wondering about something?
Answers come only from this page's reviewed material, with citations, and say plainly when the page doesn't cover it yet.
Behind this page
Who's adding to it, where it comes from, how it changed and what would make it better. Always open to everyone.
Discussion
Sources
Numbers match the citations in the article. A working link isn't proof that a page supports a claim; check the quoted passage and date.
- 1Clinical Characteristics and the Effect of Timing for Metagenomic Next-Generation Sequencing in Critically Ill Patients with SepsisInfection and Drug Resistance (He et al.)Published Dec 1, 2022Checked Oct 17, 2026
“A total of 87 patients were included and 87 samples were analyzed among these patients. The most common sample for mNGS was bronchoalveolar lavage fluid (BALF), about 84% (73/87). The positive rate of pathogens identification by mNGS was higher than conventional culture (92% vs 36%, p < 0.001). In addition to the pathogens detected by conventional culture, mNGS can detect more viruses and fungi. Based on the mNGS report, clinicians made adjustments to the antibiotic regimen for 72% patients. The multivariate binary logistic regression analysis suggested that age (OR, 1.036; 95% CI, 1.005-1.067; p = 0.021) and the sequential organ failure assessment (SOFA) score on the day of mNGS sampling were independent risk factors of death at 28 days (OR, 1.204; 95% CI, 1.038-1.397; p = 0.014). In critically ill patients with sepsis, the most common sample type for mNGS was BALF, and the positive rate of mNGS is higher than conventional cultures, especially in viruses and fungi. Meanwhile, mNGS can guide clinicians in adjusting antibiotic regimens. Age and the SOFA score on the day of mNGS sampling were independent risk factors for death.”
- 2Influence of Ongoing Antibiotic Therapy on the Detection of Pathogenic Microorganisms Using Metagenomic Next-Generation Sequencing and Blood Culture in ICU Patients.Journal of clinical medicine (Schroeder et al.)Published Jun 8, 2026Checked Oct 17, 2026
“A total of 393 paired metagenomic next-generation sequencing-blood culture samples from 302 ICU patients were analyzed. Blood culture positivity was significantly lower in patients receiving antibiotics at the time of sampling (10.4% vs. 30.4%), whereas metagenomic next-generation sequencing positivity for bacteria remained stable (52.6% vs. 50.8%). With increasing antibiotic exposure, blood culture yield declined sharply, while metagenomic next-generation sequencing detection showed minimal variation. Overall, the concordance of metagenomic next-generation sequencing compared with blood culture as a comparator was 75.3%, with a negative predictive value of 88.0%. In critically ill patients receiving antimicrobial therapy, blood culture diagnostic yield is markedly reduced, whereas plasma metagenomic next-generation sequencing maintains pathogen detection across varying durations of antibiotic exposure. Metagenomic next-generation sequencing represents a valuable complementary diagnostic tool alongside blood cultures in pretreated ICU patients.”
- 3Oxford Nanopore Sequencing, a Promising Technology for Precision Diagnostics in Intensive Care Units: A Narrative Review.Biomedicines (Azamfirei et al.)Published Aug 26, 2026Checked Oct 17, 2026
“Nanopore sequencing enables real-time, long-read, single-molecule analysis of native nucleic acid molecules, rapid pathogen identification, antimicrobial resistance profiling, metagenomic analysis, and direct sequencing without amplification. Recent studies have proved the clinical utility of nanopore sequencing in critically ill patients with sepsis, bloodstream infections, hospital-acquired pneumonia, ventilator-associated pneumonia, and fungal and viral infections. Its portability, rapid turnaround time, and potential for point-of-care implementation make it particularly attractive for ICU settings. Nanopore sequencing technology represents a promising molecular diagnostic tool, but wider clinical implementation warrants further larger studies with clinical outcome endpoints, standardized bioinformatic pipelines, and clearer validation pathways.”
- 4The value of metagenomic next-generation sequencing in lower respiratory tract infections among critically ill patients in the ICUFrontiers in Cellular and Infection Microbiology (Xu et al.)Published Feb 25, 2026Checked Oct 17, 2026
“For pathogen detection, mNGS outperformed conventional microbiological testing (CMT) in detecting bacteria and DNA viruses, while CMT had a slight advantage in RNA virus detection, though the difference was not statistically significant ( p = 0.305). When comparing microbial profiles between survival and death groups, survivors had a more diverse pathogen spectrum, particularly in bacteria and RNA viruses. There were 262 species detected in both groups, with Corynebacterium striatum being the dominant species in the survival group and Pseudomonas aeruginosa in the death group. In the 128 patients whose treatment plans were adjusted based on mNGS results, 59.4% underwent escalation, 25.8% had their medications changed, and 1.6% initiated new treatment regimens. Further follow-up revealed that mNGS - guided treatment adjustments were effective in improving clinical symptoms in 58.6% of ICU patients. A predictive model for patient outcomes was developed utilizing the random forest algorithm, achieving an area under the receiver operating characteristic curve (AUC) of 0.722.”
- 5Ten-year-old Willow among children to benefit from pioneering same-day test to spot infectionsBBC NewsPublished Oct 16, 2026Checked Oct 17, 2026
“Metagenomics offers a new way of detecting infections in intensive care patients.”
- 6Metagenomic Sequencing in the ICU for Precision Diagnosis of Critical Infectious IllnessesCritical Care (Neyton et al.)Published Mar 21, 2023Checked Oct 17, 2026
“This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2023. Other selected articles can be found online at https://www.biomedcentral.com/collections/annualupdate2023 . Further information about the Annual Update in Intensive Care and Emergency Medicine is available from https://link.springer.com/bookseries/8901 .”
How it changed
Published 1 time since Oct 17, 2026.
- Version 2Oct 17, 2026Live now
AI-prepared Starting Map from live research.
- First published version.
Help improve it
The brief is open about what's uncertain. These are the specific gaps that new material would fill.
Open questions
How much faster is mNGS than culture or PCR in hours, from sample to actionable report, in routine ICU use?
No answers yet
What are mNGS sensitivity and specificity against a composite reference standard rather than culture alone?
No answers yet
Do mNGS-guided treatment changes reduce mortality, length of stay or antibiotic use in randomised or controlled studies?
No answers yet
How often do contamination, colonisation and background flora produce misleading mNGS results in ICU samples?
No answers yet
Do the high detection rates seen with bronchoalveolar lavage hold for blood and other sample types?
No answers yet
Around this topic
Sylos connect: narrower topics report up to broader ones, so what's learned in one place shows up where it matters.